Hero banner with and AGENT DCB image and the AGENT 40 mm logo.

AGENT™ Drug-Coated Balloon for Coronary PCI

Deliver optimal healing for in-stent restenosis (ISR) and de novo lesions including small vessel disease.

A Drug-Coated Balloon you can trust – now available in 40mm

For broader lesion coverage and procedural confidence, the AGENTTM DCB is now available in 40mms to enhance deliverabilty for long lesions. Hear how Dr. Testa approaches DCB selection and deliverability.

Why choose AGENT™ Drug-Coated Balloon? 

The AGENTTM DCB is designed for optimal drug deliverability by combining a low-dose paclitaxel 2 µg/mm² and acetyl tributyl citrate (ATBC) Excipient coating technology (TransPaxTM). The coating is designed not only to protect the coating during delivery and support efficient drug transfer to the vessel wall, but to do so rapidly (30 seconds per IFU) .

Get product information
content-large

Exceptional long term clinical outcomes

Recent clinical data continues to reinforce AGENT™ Drug-Coated Balloon (DCB) as a proven solution for treating coronary artery disease. AGENT™  DCB has been used in more than 275.000 patients worldwide and studied in more than 16.000 patients across complex in-stent restenosis (ISR) and de novo populations.1

Discover the clinical data supporting AGENT™ DCB

Effortless deliverability

Created with a highly deliverable catheter, AGENTTM has a laser-bonded low-profile tip, bi-segmented inner shaft and Z-Glide. The balloon design is based on the proven EMERGETM balloon catheter so that you can reach distal or complex anatomies easily and transfer the drug efficiently in 30 seconds.

A schematic image of AGENT DCB zooming in on the deliverability benefits of the device.

Efficient drug transfer

Due to the efficiency of AGENTTM Drug-Coated Balloon’s proprietary TransPaxTM Coating Technology, AGENTTM is able to use the lowest Paclitaxel (PTx) dosage compared to other PTx-coated balloons, while still resulting in the highest concentration of drug in the tissue. This allows you to deliver the optimal dose with less balloon drug load2,3.

A graph showing higher drug tissue concentration of AGENT DCB vs SeQuent Please, Selution and Magic Touch.

The AGENTTM difference: 3 key mechanisms of action for best-in-class reliable drug transfer

TransPaxTM combines an acetyl tributyl citrate (ATBC) excipient with 2 µg/mm2 of crystalline, sharp-edge Paclitaxel (PTx),  custom engineered around 3 key mechanisms of action:

A scientific drawing of AGENT DCB in a vessel illustrating targeted transfer.

1. Targeted Transfer

The AGENT Mechanism of Action allows the drug to be transferred in 30 seconds from balloon to vessel wall.

AGENT PTx structure, Hydrophobic1 and durable under hydration in the blood stream3, combined with the ATBC excipient, act to maintain coating integrity during tracking and positioning3.

These help minimise the systemic loss of drug during tracking and inflation4,8.

A scientific drawing of AGENT DCB in a vessel illustrating rapid absorption.

2. Rapid Absorption

AGENT’s TransPaxTM coating is optimized for Rapid Absorption, with a sharp-edge PTx structure1 and ATBC excipient.

The PTx is Lipophilic1, having a high affinity for fatty tissue, and formulated to aid its rapid tissue penetration and absorption5 during the short DCB inflation time.

A scientific drawing of AGENT DCB in a vessel illustrating sustained retention.

3. Sustained Retention

AGENT’s uniform crystalline PTx formulation, dissolves more slowly in the vessel) and achieves sustained drug retention and release, up to 90 days2, 6, 7

AGENT’s PTx has a long half-life, and its chemical stability continues acting through the restenosis-prone healing phase 4.

Ordering Information
 

Ø(mm)12mm15mm20mm30mm40mm
2.00H74939222201210H74939222201510H74939222202010H74939222203010H74939222204010
2.25H74939222221210H74939222221510H74939222222010H74939222223010-
2.50H74939222251210H74939222251510H74939222252010H74939222253010H74939222254010
2.75H74939222271210H74939222271510H74939222272010H74939222273010-
3.00H74939222301210H74939222301510H74939222302010H74939222303010H74939222304010
3.50H74939222351210H74939222351510H74939222352010H74939222353010H74939222354010
4.00H74939222401210H74939222401510H74939222402010H74939222403010H74939222404010
Icon showing a browser window and mousepointer.

Explore EDUCARE online

Register to customise your learning journey with online education courses and in-person training events in your medical specialty.

Register now
Icon demonstarting PDF file.

Product catalogue

Download our product catalogue 2026 and stay up to date on our latest innovations.
 

Download now

1. Surapaneni, M., et al. "Designing Paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges." International Scholarly Research Notices (2012).​
2. Tzafriri A, et al. Journal of Controlled Release. 2019; 310:94–102.  Taking paclitaxel coated balloons to a higher level: Predicting coating dissolution kinetics, tissue retention and dosing dynamics
3. BSC Internal Test. Results of internal bench studies are not representative of clinical performance.  Clinical results may vary.
4. Speck, U,. et al., Do Pharmacokinetics Explain Persistent Restenosis Inhibition by a Single Dose of Paclitaxel?, Circ Cardiov Interv, 2012 
5. Loh, JP., et al., The current status of drug-coated balloons in percutaneous coronary and peripheral interventions, EuroIntervention 2013 
6. Tzafriri AR, et al., Taking paclitaxel coated balloons to a higher level: Predicting coating dissolution kinetics, tissue retention and dosing dynamics. J Control Release. 2019 Sep
7. Pre-clinical pharmacokinetic studies performed using the same FDA recommended and accepted porcine coronary de nevo vessel test methodBSC conducted AGENT, SeQuent Please and Selution. Magic touch published data, TCT 2020.
8. Granada JF, et al. Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing. Open Heart 2014
 

CAUTION: The information presented in this document by Boston Scientific is intended for healthcare professionals in India. [The information presented in this document is intended to provide balanced, scientific, and evidence based answers to unsolicited medical questions.] The information should not be, however, treated as comprehensive and does not intend to provide diagnosis, treatment or any medical or health advice. For full information about the product, please refer to the appropriate product labeling. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional licence, experience and knowledge of the patient. Healthcare professionals must rely on their judgment when deciding which treatments and procedures to use with patients.

Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. Please check availability with your local sales representative or customer service.

All images are the property of Boston Scientific. All trademarks are the property of their respective owners.